Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000941304 | SCV001087187 | benign | X-linked severe combined immunodeficiency | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003372919 | SCV004093768 | uncertain significance | Inborn genetic diseases | 2023-09-13 | criteria provided, single submitter | clinical testing | The c.281C>T (p.S94L) alteration is located in exon 3 (coding exon 3) of the IL2RG gene. This alteration results from a C to T substitution at nucleotide position 281, causing the serine (S) at amino acid position 94 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003895722 | SCV004714750 | likely benign | IL2RG-related disorder | 2023-12-23 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Natera, |
RCV000941304 | SCV001467118 | likely benign | X-linked severe combined immunodeficiency | 2020-10-10 | no assertion criteria provided | clinical testing |